Largest biotech by market cap
CRISPR Therapeutics has the lowest figure of the 24 biotech ranked by market value, at NOK 37.6B, followed by Adaptive Biotechnologies (NOK 44.6B) and Scholar Rock Holding (NOK 53.2B). Figures as of 18 Nov 2026, 13:00 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- Lowest
- CRISPR TherapeuticsNOK 37.6B
- Median
- NOK 100.2B
- Combined market value
- NOK 8.21T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | Market cap ↑ | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|
| 1 | CRISPR TherapeuticsCRSP · Health Care | NOK 37.6B | NOK 388.06 | 0.54% down | 21% down | ||
| 2 | Adaptive BiotechnologiesADPT · Health Care | NOK 44.6B | NOK 275.36 | 2.22% up | 88% up | ||
| 3 | Scholar Rock HoldingSRRK · Health Care | NOK 53.2B | NOK 435.70 | 1.21% up | 14% up | ||
| 4 | Kodiak SciencesKOD · Health Care | NOK 61.2B | NOK 935.59 | 3.90% down | 396% up | ||
| 5 | ImmunityBioIBRX · Health Care | NOK 64.4B | NOK 60.50 | 4.68% up | 193% up | ||
| 6 | ImmunovantIMVT · Health Care | NOK 66.4B | NOK 320.98 | 0.21% down | 43% up | ||
| 7 | CG OncologyCGON · Health Care | NOK 68.1B | NOK 762.97 | 6.89% down | 85% up | ||
| 8 | Twist BioscienceTWST · Health Care | NOK 73.8B | NOK 1,082.50 | 6.63% up | 340% up | ||
| 9 | Krystal BiotechKRYS · Health Care | NOK 85.5B | NOK 2,885.53 | 0.22% up | 46% up | ||
| 10 | VaxcytePCVX · Health Care | NOK 90.9B | NOK 574.11 | 3.59% down | 22% up | ||
| 11 | QiagenQGEN · Health Care | NOK 99.3B | NOK 480.84 | 0.12% down | 12% up | ||
| 12 | RepligenRGEN · Health Care | NOK 100.2B | NOK 1,567.49 | 0.37% down | 5% up | ||
| 13 | Kymera TherapeuticsKYMR · Health Care | NOK 100.3B | NOK 1,174.51 | 3.44% down | 87% up | ||
| 14 | Halozyme TherapeuticsHALO · Health Care | NOK 105.8B | NOK 927.56 | 0.55% down | 37% up | ||
| 15 | Bio-TechneTECH · Health Care | NOK 110.3B | NOK 701.98 | 0.22% down | 26% up | ||
| 16 | ExelixisEXEL · Health Care | NOK 161.6B | NOK 662.06 | 2.09% up | 63% up | ||
| 17 | Neurocrine BiosciencesNBIX · Health Care | NOK 162.3B | NOK 1,603.64 | 0.37% up | 20% up | ||
| 18 | BioNTechBNTX · Health Care | NOK 203.3B | NOK 820.18 | 0.47% down | 16% down | ||
| 19 | Revolution MedicinesRVMD · Health Care | NOK 340.1B | NOK 1,572.42 | 2.50% down | 131% up | ||
| 20 | BiogenBIIB · Health Care | NOK 358.3B | NOK 2,423.92 | 0.34% down | 49% up | ||
| 21 | argenxARGX · Health Care | NOK 575.9B | NOK 9,157.91 | 0.36% down | 4% up | ||
| 22 | ModernaMRNA · Health Care | NOK 808.7B | NOK 1,998.75 | 3.93% down | 755% up | ||
| 23 | Gilead SciencesGILD · Health Care | NOK 2.04T | NOK 1,645.59 | 1.60% up | 33% up | ||
| 24 | AmgenAMGN · Health Care | NOK 2.39T | NOK 4,425.96 | 0.95% down | 34% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6651 NOK).
Questions and answers
Which biotech have the lowest market cap?
CRISPR Therapeutics (NOK 37.6B), Adaptive Biotechnologies (NOK 44.6B) and Scholar Rock Holding (NOK 53.2B) have the lowest market cap of the 24 biotech ranked here as of 18 Nov 2026, 13:00 UTC.
How many biotech are in this ranking?
24 are ranked by market value.
What are these biotech worth together?
The 24 biotech ranked by market value have a combined market value of NOK 8.21T as of 18 Nov 2026, 13:00 UTC.
What does ranking by market value measure?
What the stock market values the whole company at: its share price times the number of its shares.
Learn how this ranking works
All markets guides →- What market capitalization is, and what it is not
Market capitalization is the share price multiplied by the number of shares outstanding: 1 billion shares at $50 is a $50 billion company. It measures the size the stock market puts on a company's equity today. It is not a sale price, it ignores debt and cash, and index providers often count only the freely traded part, the float.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest biotech by market cap”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech
Underlying data: Yahoo Finance; SEC EDGAR.